Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Elutia Inc ELUT

Healthcare Biotechnology
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use... see more

Recent & Breaking News (NDAQ:ELUT)

Aziyo Biologics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

GlobeNewswire August 17, 2022

Aziyo Biologics Announces Second Quarter 2022 Financial Results and Recent Business Achievements, Including Robust Revenue Growth and Strengthened Balance Sheet

GlobeNewswire August 11, 2022

Aziyo Biologics Announces $25 Million Loan Facility with SWK Holdings

GlobeNewswire August 10, 2022

Aziyo Biologics Co-Founder and Regenerative Medicine Pioneer, Dr. Randy Mills, appointed Chief Executive Officer

GlobeNewswire August 9, 2022

Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022

GlobeNewswire July 28, 2022

Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO

GlobeNewswire June 21, 2022

Aziyo Biologics Provides Business Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 9, 2022

Aziyo Biologics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022

GlobeNewswire April 25, 2022

Aziyo Biologics Announces Upcoming KOL Call Hosted by Cowen

GlobeNewswire April 12, 2022

Aziyo Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics

GlobeNewswire April 4, 2022

Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference

GlobeNewswire March 31, 2022

Aziyo Biologics Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 3, 2022

Aziyo Biologics to Participate in the Cowen 42nd Annual Health Care Conference

GlobeNewswire February 23, 2022

Aziyo Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022

GlobeNewswire February 17, 2022

Aziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual Conference

GlobeNewswire December 27, 2021

Aziyo Biologics Announces Closing of $14.0 Million Private Placement

GlobeNewswire December 8, 2021

Aziyo Biologics Announces $14.0 Million Private Placement

GlobeNewswire December 6, 2021

Aziyo Biologics to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire November 15, 2021

Aziyo Biologics Reports Third Quarter 2021 Financial Results

GlobeNewswire November 9, 2021

Aziyo Biologics Provides Business Update and Preliminary Third Quarter 2021 Revenue Results and Announces Timing for Third Quarter 2021 Financial Results

GlobeNewswire October 25, 2021